Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VEGF Trap-Eye: Additional Phase II data

In a double-blind Phase II trial in 157 patients, VEGF Trap-Eye significantly reduced baseline retinal thickness after 12

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE